Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)
Status:
Completed
Trial end date:
2019-09-25
Target enrollment:
Participant gender:
Summary
This was a Phase 1, open-label, dose-escalation trial of avelumab (antibody targeting
programmed death ligand 1 [anti PD-L1]) in Japanese participants with metastatic or locally
advanced solid tumors, followed by a consecutive expansion part in Asian participants with
gastric cancer.